文献速递中枢神经肿瘤放疗放疗物理与技术

基于生物学靶区定义的剂量强化放化疗治疗新诊断胶质母细胞瘤的2期研究

A Phase 2 Study of Dose-intensified Chemoradiation Using Biologically Based Target Volume Definition in Patients With Newly Diagnosed Glioblastoma.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2021-01-29

这项单臂2期试验纳入26例新诊断胶质母细胞瘤患者,针对高细胞密度(TVHCV)和高灌注(TVCBV)肿瘤区域进行剂量强化至75 Gy并联合替莫唑胺。强化至TVHCV/TVCBV联合区域的13例患者12个月总生存率为92%,3个月时TVHCV/TVCBV缩小至中位体积以下者总生存更优,神经认知功能与生活质量下降发生率与标准治疗相似。

要点

  • 针对高细胞密度和高灌注区域的剂量强化放化疗可行,12个月OS率达92%。
  • 3个月时TVHCV/TVCBV缩小至中位体积以下者总生存显著更优。
  • 晚期3级神经毒性仅2例,神经认知与生活质量下降与标准治疗相似。

核心结论

  • 针对胶质母细胞瘤高细胞密度和高灌注区域的剂量强化放化疗可获得有前景的总生存,且神经认知功能、症状负担和生活质量结局良好。

研究设计与样本

  • 单臂2期试验纳入26例新诊断胶质母细胞瘤成人患者,TVHCV/TVCBV>1 cm3者接受30次共75 Gy照射联合替莫唑胺。

主要发现

  • 强化至TVHCV/TVCBV联合区域的13例患者12个月OS率为92%(95%CI 78%-100%,P=.03),中位OS为20个月(95%CI 18-未达到)。
  • 全研究队列中位OS为20个月(95%CI 14-29个月)。
  • 3个月时TVHCV/TVCBV缩小至低于中位体积3 cm3者总生存更优(29 vs 12个月,P=.02)。
  • 仅5例出现中心或野内失败,11C-甲硫氨酸代谢肿瘤体积的高剂量覆盖率为93%(四分位距59%-100%)。
  • 晚期3级神经毒性发生于2例患者;未进展患者中1个月和7个月生活质量、症状及神经认知功能下降发生率与标准治疗相似。

临床怎么用

  • 可考虑对高细胞密度和高灌注区域进行剂量强化至75 Gy并联合替莫唑胺,但需关注晚期神经毒性。
  • 放疗后3个月TVHCV/TVCBV缩小程度可能有助于判断预后。

局限性

  • 单臂设计,样本量较小(26例),部分患者仅强化TVHCV而非联合区域。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: We hypothesized that dose-intensified chemoradiation therapy targeting adversely prognostic hypercellular (TVHCV) and hyperperfused (TVCBV) tumor volumes would improve outcomes in patients with glioblastoma. METHODS AND MATERIALS: This single-arm, phase 2 trial enrolled adult patients with newly diagnosed glioblastoma. Patients with a TVHCV/TVCBV >1 cm3, identified using high b-value diffusion-weighted magnetic resonance imaging (MRI) and dynamic contrast-enhanced perfusion MRI, were treated over 30 fractions to 75 Gy to the TVHCV/TVCBV with temozolomide. The primary objective was to estimate improvement in 12-month overall survival (OS) versus historical control. Secondary objectives included evaluating the effect of 3-month TVHCV/TVCBV reduction on OS using Cox proportional-hazard regression and characterizing coverage (95% isodose line) of metabolic tumor volumes identified using correlative 11C-methionine positron emission tomography. Clinically meaningful change was assessed for quality of life by the European Organisation for the Research and Treatment of Cancer Quality of Life Questionnaire C30, for symptom burden by the MD Anderson Symptom Inventory for brain tumor, and for neurocognitive function (NCF) by the Controlled Oral Word Association Test, the Trail Making Test, parts A and B, and the Hopkins Verbal Learning Test-Revised. RESULTS: Between 2016 and 2018, 26 patients were enrolled. Initial patients were boosted to TVHCV alone, and 13 patients were boosted to both TVHCV/TVCBV. Gross or subtotal resection was performed in 87% of patients; 22% were O6-methylguanine-DNA methyltransferase (MGMT) methylated. With 26-month follow-up (95% CI, 19-not reached), the 12-month OS rate among patients boosted to the combined TVHCV/TVCBV was 92% (95% CI, 78%-100%; P = .03) and the median OS was 20 months (95% CI, 18-not reached); the median OS for the whole study cohort was 20 months (95% CI, 14-29 months). Patients whose 3-month TVHCV/TVCBV decreased to less than the median volume (3 cm3) had superior OS (29 vs 12 months; P = .02). Only 5 patients had central or in-field failures, and 93% (interquartile range, 59%-100%) of the 11C-methionine metabolic tumor volumes received high-dose coverage. Late grade 3 neurologic toxicity occurred in 2 patients. Among non-progressing patients, 1-month and 7-month deterioration in quality of life, symptoms, and NCF were similar in incidence to standard therapy. CONCLUSIONS: Dose intensification against hypercellular/hyperperfused tumor regions in glioblastoma yields promising OS with favorable outcomes for NCF, symptom burden, and quality of life, particularly among patients with greater tumor reduction 3 months after radiation therapy.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Kim MM, Sun Y, Aryal MP, et al. A Phase 2 Study of Dose-intensified Chemoradiation Using Biologically Based Target Volume Definition in Patients With Newly Diagnosed Glioblastoma. Int J Radiat Oncol Biol Phys. 2021. PMID: 33524546. doi:10.1016/j.ijrobp.2021.01.033

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。